NCT02598583View on ClinicalTrials.gov

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 12, 2015

Primary Completion Date

July 14, 2016

Study Completion Date

March 11, 2021

Conditions
PNH
Interventions
BIOLOGICAL

ALXN1210

Participants were administered ravulizumab as an IV infusion every 4 weeks.

Trial Locations (8)

2170

Clinical Trial Site, Liverpool

4102

Clinical Trial Site, Woolloongabba

44033

Clinical Trial Site, Ulsan

03080

Clinical Trial Site, Seoul

03722

Clinical Trial Site, Seoul

05505

Clinical Trial Site, Seoul

06351

Clinical Trial Site, Seoul

06951

Clinical Trial Site, Seoul

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY